Clinical Trial Detail

NCT ID NCT01657682
Title A Phase II Study of Crenolanib in Relapsed/Refractory Acute Myeloid Leukemia Patients With FLT3 Activating Mutations
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Arog Pharmaceuticals LLC
Indications

acute myeloid leukemia

Therapies

Crenolanib

Age Groups: adult

Additional content available in CKB BOOST